SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Sarepta Therapeutics, Inc. – ‘10-K’ for 12/31/19 – ‘EX-101.SCH’

On:  Wednesday, 2/26/20, at 4:04pm ET   ·   For:  12/31/19   ·   Accession #:  1564590-20-6769   ·   File #:  1-14895

Previous ‘10-K’:  ‘10-K’ on 2/28/19 for 12/31/18   ·   Next:  ‘10-K’ on 3/1/21 for 12/31/20   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23   ·   9 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/26/20  Sarepta Therapeutics, Inc.        10-K       12/31/19  129:25M                                    ActiveDisclosure/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        2019 Form 10-K                                      HTML   2.41M 
 2: EX-4.4      Instrument Defining the Rights of Security Holders  HTML     46K 
 3: EX-10.51    Material Contract                                   HTML    787K 
 4: EX-10.52    Material Contract                                   HTML    169K 
 5: EX-10.53    Material Contract                                   HTML    725K 
 6: EX-10.54    Material Contract                                   HTML    224K 
 7: EX-10.55    Material Contract                                   HTML     51K 
 8: EX-10.56    Material Contract                                   HTML     50K 
 9: EX-10.57    Material Contract                                   HTML     39K 
10: EX-21.1     Subsidiaries List                                   HTML     33K 
11: EX-23.1     Consent of Experts or Counsel                       HTML     37K 
12: EX-31.1     Certification -- §302 - SOA'02                      HTML     39K 
13: EX-31.2     Certification -- §302 - SOA'02                      HTML     39K 
14: EX-32.1     Certification -- §906 - SOA'02                      HTML     37K 
15: EX-32.2     Certification -- §906 - SOA'02                      HTML     37K 
121: R1          Document and Entity Information                     HTML     99K  
49: R2          Consolidated Balance Sheets                         HTML    118K 
36: R3          Consolidated Balance Sheets (Parenthetical)         HTML     53K 
78: R4          Consolidated Statements of Operations and           HTML    101K 
                Comprehensive Loss                                               
120: R5          Consolidated Statements of Stockholders' Equity     HTML    104K  
48: R6          Consolidated Statements of Cash Flows               HTML    181K 
35: R7          Organization and Nature of Business                 HTML     40K 
77: R8          Summary of Significant Accounting Policies and      HTML    121K 
                Recent Accounting Pronouncements                                 
122: R9          License and Collaboration Agreements                HTML    106K  
30: R10         Gain From Sale of Priority Review Voucher           HTML     36K 
70: R11         Fair Value Measurements                             HTML    183K 
114: R12         Cash, Cash Equivalents and Marketable Securities    HTML    190K  
98: R13         Accounts Receivable and Reserves for Product Sales  HTML    136K 
31: R14         Inventory                                           HTML     56K 
71: R15         Other Assets                                        HTML    103K 
115: R16         Property and Equipment, Net                         HTML     84K  
99: R17         Intangible Assets                                   HTML     83K 
32: R18         Accrued Expenses                                    HTML     76K 
69: R19         Indebtedness                                        HTML    110K 
118: R20         Equity                                              HTML     39K  
74: R21         Stock-Based Compensation                            HTML    548K 
37: R22         401 (K) Plan                                        HTML     38K 
50: R23         Other (Loss) Income                                 HTML     73K 
119: R24         Income Taxes                                        HTML    298K  
75: R25         Leases                                              HTML    106K 
38: R26         Net Loss Per Share                                  HTML     70K 
51: R27         Commitments and Contingencies                       HTML     76K 
117: R28         Subsequent Event                                    HTML     38K  
76: R29         Financial Information by Quarter (Unaudited)        HTML    320K 
97: R30         Summary of Significant Accounting Policies and      HTML    183K 
                Recent Accounting Pronouncements (Policies)                      
112: R31         Summary of Significant Accounting Policies and      HTML     47K  
                Recent Accounting Pronouncements (Tables)                        
73: R32         License and Collaboration Agreements (Tables)       HTML     65K 
34: R33         Fair Value Measurements (Tables)                    HTML    180K 
95: R34         Cash, Cash Equivalents and Marketable Securities    HTML    190K 
                (Tables)                                                         
111: R35         Accounts Receivable and Reserves for Product Sales  HTML    139K  
                (Tables)                                                         
72: R36         Inventory (Tables)                                  HTML     58K 
33: R37         Other Assets (Tables)                               HTML    105K 
94: R38         Property and Equipment, Net (Tables)                HTML     84K 
113: R39         Intangible Assets (Table)                           HTML     82K  
85: R40         Accrued Expenses (Tables)                           HTML     75K 
128: R41         Indebtedness (Tables)                               HTML     99K  
53: R42         Stock-Based Compensation (Tables)                   HTML    557K 
41: R43         Other (Loss) Income (Tables)                        HTML     73K 
84: R44         Income Taxes (Tables)                               HTML    298K 
127: R45         Leases (Tables)                                     HTML    109K  
52: R46         Net Loss Per Share (Tables)                         HTML     70K 
39: R47         Commitments and Contingencies (Tables)              HTML     51K 
83: R48         Financial Information by Quarter (Unaudited)        HTML    320K 
                (Tables)                                                         
129: R49         Organization and Nature of Business - Additional    HTML     49K  
                Information (Detail)                                             
109: R50         Summary of Significant Accounting Policies and      HTML     78K  
                Recent Accounting Pronouncements - Additional                    
                Information (Detail)                                             
90: R51         Summary of Estimated Useful Lives of Plant and      HTML     60K 
                Equipment (Detail)                                               
22: R52         License and Collaboration Agreements - Additional   HTML    325K 
                Information (Detail)                                             
60: R53         Schedule of Total Consideration of Business         HTML     66K 
                Acquisition (Details)                                            
110: R54         Gain From Sale of Priority Review Voucher -         HTML     39K  
                Additional Information (Detail)                                  
91: R55         Assets and Liabilities Measured and Carried at      HTML     71K 
                Fair Value (Detail)                                              
23: R56         Summary of Company Financial Assets with            HTML     43K 
                Maturities of Less Than 90 Days Included in Cash                 
                Equivalents (Detail)                                             
61: R57         Cash, Cash Equivalents and Marketable Securities -  HTML     36K 
                Additional Information (Detail)                                  
107: R58         Summary of Company Cash, Cash Equivalents and       HTML     82K  
                Investments (Detail)                                             
93: R59         Summary of Components of Accounts Receivable        HTML     43K 
                (Detail)                                                         
43: R60         Summary of Change in Reserves for Discounts and     HTML     54K 
                Allowances (Detail)                                              
57: R61         Summary of Total Reserves Included in Consolidated  HTML     41K 
                Balance Sheets (Detail)                                          
124: R62         Inventory - Summary of Components of Inventory      HTML     47K  
                (Detail)                                                         
80: R63         Summary of Other Current Assets (Detail)            HTML     54K 
44: R64         Summary of Other Non-current Assets (Detail)        HTML     50K 
58: R65         Summarizes Components of Property and Equipment,    HTML     64K 
                Net (Detail)                                                     
125: R66         Property and Equipment, Net - Additional            HTML     37K  
                Information (Detail)                                             
81: R67         Intangible Assets - Summary of Components of        HTML     48K 
                Intangible Assets (Detail)                                       
47: R68         Intangible Assets - Additional Information          HTML     70K 
                (Detail)                                                         
55: R69         Intangible Assets - Summary of Estimated Future     HTML     50K 
                Amortization for Intangible Assets (Detail)                      
65: R70         Summary of Accrued Expenses (Detail)                HTML     58K 
28: R71         Indebtedness - Additional Information (Detail)      HTML    143K 
88: R72         Indebtedness - Summary of Debt Facilities (Detail)  HTML     57K 
102: R73         Indebtedness - Summarizes Total Gross Payments Due  HTML     42K  
                under Company's Debt Arrangements (Detail)                       
64: R74         Equity - Additional Information (Detail)            HTML     55K 
27: R75         Stock Based Compensation - Additional Information   HTML    153K 
                (Detail)                                                         
87: R76         Assumptions for Measuring Fair Values of Stocks     HTML     58K 
                (Detail)                                                         
101: R77         Assumptions for Measuring Fair Values of Stocks     HTML     36K  
                (Parenthetical) (Detail)                                         
67: R78         Summary of Stock Option Activity (Detail)           HTML     92K 
24: R79         Summary of Stock Option Activity (Parenthetical)    HTML     45K 
                (Detail)                                                         
66: R80         Summary of Company's Stock Options Vested and       HTML     39K 
                Exercised (Detail)                                               
29: R81         Summary of Restricted Stock Award Activity          HTML     59K 
                (Detail)                                                         
89: R82         Summary of Restricted Stock Unit Activity (Detail)  HTML     59K 
103: R83         Summary of Stock Appreciation Rights Activity       HTML     56K  
                (Detail)                                                         
63: R84         Summary of Employee Stock Purchase Plan Activity    HTML     42K 
                and Expense (Detail)                                             
26: R85         Summary of Stock-Based Compensation Expense by      HTML     43K 
                Function Included within Consolidated Statements                 
                of Operations and Comprehensive Loss (Detail)                    
86: R86         Summary of Stock-Based Compensation Expense by      HTML     45K 
                Grant Type Included within Consolidated Statements               
                of Operations and Comprehensive Loss (Detail)                    
100: R87         401 (K) PLAN - Additional Information (Detail)      HTML     47K  
68: R88         Summary of Other (Loss) Income (Detail)             HTML     53K 
25: R89         Summary of Loss before Provision for Income Taxes   HTML     47K 
                by Jurisdiction (Detail)                                         
42: R90         Summary of Provision for Income Taxes (Detail)      HTML     70K 
56: R91         Reconciliation Between Effective Tax Rate and       HTML     65K 
                Federal Income Tax Rate (Detail)                                 
123: R92         Income Taxes - Additional Information (Detail)      HTML     94K  
79: R93         Analysis of Deferred Tax Assets and Liabilities     HTML     72K 
                (Detail)                                                         
45: R94         Reconciliation of Beginning and Ending Amount of    HTML     45K 
                Unrecognized Tax Benefits (Detail)                               
59: R95         Leases - Additional Information (Detail)            HTML     46K 
126: R96         Summary of Lease Costs Recognized Under Topic 842   HTML     51K  
                and Other Information Pertaining to Operating                    
                Leases (Detail)                                                  
82: R97         Summary of Maturities of Lease Liabilities and      HTML     63K 
                Reconciliation of Lease Liabilities Recognized                   
                Under Topic 842 (Detail)                                         
46: R98         Summary of Aggregate Future Minimum                 HTML     55K 
                Non-Cancellable Commitments under Leases (Detail)                
54: R99         Basic and Diluted Net Loss Per Share (Detail)       HTML     51K 
106: R100        Basic and Diluted Net Loss Per Share                HTML     48K  
                (Parenthetical) (Detail)                                         
92: R101        Commitments and Contingencies - Additional          HTML    109K 
                Information (Detail)                                             
21: R102        Summary of Non-Cancelable Contractual Obligations   HTML     47K 
                Arising From Long-term Contractual Arrangements                  
                (Detail)                                                         
62: R103        Subsequent Event - Additional Information           HTML     38K 
                (Details)                                                        
104: R104        Financial Information by Quarter (Detail)           HTML    100K  
96: XML         IDEA XML File -- Filing Summary                      XML    232K 
40: XML         XBRL Instance -- srpt-10k_20191231_htm               XML   5.81M 
108: EXCEL       IDEA Workbook of Financial Reports                  XLSX    145K  
17: EX-101.CAL  XBRL Calculations -- srpt-20191231_cal               XML    342K 
18: EX-101.DEF  XBRL Definitions -- srpt-20191231_def                XML    936K 
19: EX-101.LAB  XBRL Labels -- srpt-20191231_lab                     XML   2.10M 
20: EX-101.PRE  XBRL Presentations -- srpt-20191231_pre              XML   1.60M 
16: EX-101.SCH  XBRL Schema -- srpt-20191231                         XSD    330K 
116: JSON        XBRL Instance as JSON Data -- MetaLinks              537±   883K  
105: ZIP         XBRL Zipped Folder -- 0001564590-20-006769-xbrl      Zip    863K

‘EX-101.SCH’   —   XBRL Schema — srpt-20191231

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date : 2020-02-26T18:39:35.4718655+00:00 -->
<!-- Version : 5.0.1.321 -->
<!-- Package ID : d69c62952c5c4b31bff675c5f7b987de -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srpt="http://www.sareptatherapeutics.com/20191231" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sareptatherapeutics.com/20191231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
<xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
<xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
<xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31"/>
<xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric"/>
<xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31"/>
<xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"/>
<xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated"/>
<xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31"/>
<xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31"/>
<xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31"/>
<xsd:annotation>
<xsd:appinfo>
<link:roleType id="TemplateLink" roleURI="http://www.sareptatherapeutics.com/20191231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
<link:definition> 00000 - Document - Template Link </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="srpt-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="srpt-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="srpt-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="srpt-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple"/>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
<link:definition> 100000 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
<link:definition> 100010 - Statement - Consolidated Balance Sheets </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
<link:definition> 100020 - Statement - Consolidated Balance Sheets (Parenthetical) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition> 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
<link:definition> 100040 - Statement - Consolidated Statements of Stockholders' Equity </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
<link:definition> 100050 - Statement - Consolidated Statements of Cash Flows </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureORGANIZATIONANDNATUREOFBUSINESS" id="Role_DisclosureORGANIZATIONANDNATUREOFBUSINESS">
<link:definition> 100060 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESANDRECENTACCOUNTINGPRONOUNCEMENTS" id="Role_DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESANDRECENTACCOUNTINGPRONOUNCEMENTS">
<link:definition> 100070 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureLICENSEANDCOLLABORATIONAGREEMENTS" id="Role_DisclosureLICENSEANDCOLLABORATIONAGREEMENTS">
<link:definition> 100080 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureGAINFROMSALEOFPRIORITYREVIEWVOUCHER" id="Role_DisclosureGAINFROMSALEOFPRIORITYREVIEWVOUCHER">
<link:definition> 100090 - Disclosure - GAIN FROM SALE OF PRIORITY REVIEW VOUCHER </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureFAIRVALUEMEASUREMENTS" id="Role_DisclosureFAIRVALUEMEASUREMENTS">
<link:definition> 100100 - Disclosure - FAIR VALUE MEASUREMENTS </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIES" id="Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIES">
<link:definition> 100110 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureACCOUNTSRECEIVABLEANDRESERVESFORPRODUCTSALES" id="Role_DisclosureACCOUNTSRECEIVABLEANDRESERVESFORPRODUCTSALES">
<link:definition> 100120 - Disclosure - ACCOUNTS RECEIVABLE AND RESERVES FOR PRODUCT SALES </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureINVENTORY" id="Role_DisclosureINVENTORY">
<link:definition> 100130 - Disclosure - INVENTORY </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureOTHERASSETS" id="Role_DisclosureOTHERASSETS">
<link:definition> 100140 - Disclosure - OTHER ASSETS </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosurePROPERTYANDEQUIPMENTNET" id="Role_DisclosurePROPERTYANDEQUIPMENTNET">
<link:definition> 100150 - Disclosure - PROPERTY AND EQUIPMENT, NET </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureINTANGIBLEASSETS" id="Role_DisclosureINTANGIBLEASSETS">
<link:definition> 100160 - Disclosure - INTANGIBLE ASSETS </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureACCRUEDEXPENSES" id="Role_DisclosureACCRUEDEXPENSES">
<link:definition> 100170 - Disclosure - ACCRUED EXPENSES </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureINDEBTEDNESS" id="Role_DisclosureINDEBTEDNESS">
<link:definition> 100180 - Disclosure - INDEBTEDNESS </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureEQUITY" id="Role_DisclosureEQUITY">
<link:definition> 100190 - Disclosure - EQUITY </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSTOCKBASEDCOMPENSATION" id="Role_DisclosureSTOCKBASEDCOMPENSATION">
<link:definition> 100200 - Disclosure - STOCK-BASED COMPENSATION </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/Disclosure401KPLAN" id="Role_Disclosure401KPLAN">
<link:definition> 100210 - Disclosure - 401 (K) PLAN </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureOTHERLOSSINCOME" id="Role_DisclosureOTHERLOSSINCOME">
<link:definition> 100220 - Disclosure - OTHER (LOSS) INCOME </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureINCOMETAXES" id="Role_DisclosureINCOMETAXES">
<link:definition> 100230 - Disclosure - INCOME TAXES </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureLEASES" id="Role_DisclosureLEASES">
<link:definition> 100240 - Disclosure - LEASES </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureNETLOSSPERSHARE" id="Role_DisclosureNETLOSSPERSHARE">
<link:definition> 100250 - Disclosure - NET LOSS PER SHARE </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureCOMMITMENTSANDCONTINGENCIES" id="Role_DisclosureCOMMITMENTSANDCONTINGENCIES">
<link:definition> 100260 - Disclosure - COMMITMENTS AND CONTINGENCIES </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSUBSEQUENTEVENT" id="Role_DisclosureSUBSEQUENTEVENT">
<link:definition> 100270 - Disclosure - SUBSEQUENT EVENT </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureFINANCIALINFORMATIONBYQUARTERUNAUDITED" id="Role_DisclosureFINANCIALINFORMATIONBYQUARTERUNAUDITED">
<link:definition> 100280 - Disclosure - FINANCIAL INFORMATION BY QUARTER (UNAUDITED) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" id="Role_DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies">
<link:definition> 100290 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESANDRECENTACCOUNTINGPRONOUNCEMENTSTables" id="Role_DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESANDRECENTACCOUNTINGPRONOUNCEMENTSTables">
<link:definition> 100300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureLICENSEANDCOLLABORATIONAGREEMENTSTables" id="Role_DisclosureLICENSEANDCOLLABORATIONAGREEMENTSTables">
<link:definition> 100310 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureFAIRVALUEMEASUREMENTSTables" id="Role_DisclosureFAIRVALUEMEASUREMENTSTables">
<link:definition> 100320 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables" id="Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables">
<link:definition> 100330 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureACCOUNTSRECEIVABLEANDRESERVESFORPRODUCTSALESTables" id="Role_DisclosureACCOUNTSRECEIVABLEANDRESERVESFORPRODUCTSALESTables">
<link:definition> 100340 - Disclosure - ACCOUNTS RECEIVABLE AND RESERVES FOR PRODUCT SALES (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureINVENTORYTables" id="Role_DisclosureINVENTORYTables">
<link:definition> 100350 - Disclosure - INVENTORY (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureOTHERASSETSTables" id="Role_DisclosureOTHERASSETSTables">
<link:definition> 100360 - Disclosure - OTHER ASSETS (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosurePROPERTYANDEQUIPMENTNETTables" id="Role_DisclosurePROPERTYANDEQUIPMENTNETTables">
<link:definition> 100370 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureINTANGIBLEASSETSTable" id="Role_DisclosureINTANGIBLEASSETSTable">
<link:definition> 100380 - Disclosure - INTANGIBLE ASSETS (Table) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureACCRUEDEXPENSESTables" id="Role_DisclosureACCRUEDEXPENSESTables">
<link:definition> 100390 - Disclosure - ACCRUED EXPENSES (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureINDEBTEDNESSTables" id="Role_DisclosureINDEBTEDNESSTables">
<link:definition> 100400 - Disclosure - INDEBTEDNESS (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSTOCKBASEDCOMPENSATIONTables" id="Role_DisclosureSTOCKBASEDCOMPENSATIONTables">
<link:definition> 100410 - Disclosure - STOCK-BASED COMPENSATION (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureOTHERLOSSINCOMETables" id="Role_DisclosureOTHERLOSSINCOMETables">
<link:definition> 100420 - Disclosure - OTHER (LOSS) INCOME (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureINCOMETAXESTables" id="Role_DisclosureINCOMETAXESTables">
<link:definition> 100430 - Disclosure - INCOME TAXES (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureLEASESTables" id="Role_DisclosureLEASESTables">
<link:definition> 100440 - Disclosure - LEASES (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureNETLOSSPERSHARETables" id="Role_DisclosureNETLOSSPERSHARETables">
<link:definition> 100450 - Disclosure - NET LOSS PER SHARE (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureCOMMITMENTSANDCONTINGENCIESTables" id="Role_DisclosureCOMMITMENTSANDCONTINGENCIESTables">
<link:definition> 100460 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureFINANCIALINFORMATIONBYQUARTERUNAUDITEDTables" id="Role_DisclosureFINANCIALINFORMATIONBYQUARTERUNAUDITEDTables">
<link:definition> 100470 - Disclosure - FINANCIAL INFORMATION BY QUARTER (UNAUDITED) (Tables) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail" id="Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail">
<link:definition> 100480 - Disclosure - Organization and Nature of Business - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetail">
<link:definition> 100490 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfEstimatedUsefulLivesOfPlantAndEquipmentDetail" id="Role_DisclosureSummaryOfEstimatedUsefulLivesOfPlantAndEquipmentDetail">
<link:definition> 100500 - Disclosure - Summary of Estimated Useful Lives of Plant and Equipment (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" id="Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail">
<link:definition> 100510 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureScheduleOfTotalConsiderationOfBusinessAcquisitionDetails" id="Role_DisclosureScheduleOfTotalConsiderationOfBusinessAcquisitionDetails">
<link:definition> 100520 - Disclosure - Schedule of Total Consideration of Business Acquisition (Details) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureGainFromSaleOfPriorityReviewVoucherAdditionalInformationDetail" id="Role_DisclosureGainFromSaleOfPriorityReviewVoucherAdditionalInformationDetail">
<link:definition> 100530 - Disclosure - Gain From Sale of Priority Review Voucher - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" id="Role_DisclosureAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail">
<link:definition> 100540 - Disclosure - Assets and Liabilities Measured and Carried at Fair Value (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90DaysIncludedInCashEquivalentsDetail" id="Role_DisclosureSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90DaysIncludedInCashEquivalentsDetail">
<link:definition> 100550 - Disclosure - Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" id="Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail">
<link:definition> 100560 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfCompanyCashCashEquivalentsAndInvestmentsDetail" id="Role_DisclosureSummaryOfCompanyCashCashEquivalentsAndInvestmentsDetail">
<link:definition> 100570 - Disclosure - Summary of Company Cash, Cash Equivalents and Investments (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfComponentsOfAccountsReceivableDetail" id="Role_DisclosureSummaryOfComponentsOfAccountsReceivableDetail">
<link:definition> 100580 - Disclosure - Summary of Components of Accounts Receivable (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfChangeInReservesForDiscountsAndAllowancesDetail" id="Role_DisclosureSummaryOfChangeInReservesForDiscountsAndAllowancesDetail">
<link:definition> 100590 - Disclosure - Summary of Change in Reserves for Discounts and Allowances (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfTotalReservesIncludedInConsolidatedBalanceSheetsDetail" id="Role_DisclosureSummaryOfTotalReservesIncludedInConsolidatedBalanceSheetsDetail">
<link:definition> 100600 - Disclosure - Summary of Total Reserves Included in Consolidated Balance Sheets (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureInventorySummaryOfComponentsOfInventoryDetail" id="Role_DisclosureInventorySummaryOfComponentsOfInventoryDetail">
<link:definition> 100610 - Disclosure - Inventory - Summary of Components of Inventory (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfOtherCurrentAssetsDetail" id="Role_DisclosureSummaryOfOtherCurrentAssetsDetail">
<link:definition> 100620 - Disclosure - Summary of Other Current Assets (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfOtherNonCurrentAssetsDetail" id="Role_DisclosureSummaryOfOtherNonCurrentAssetsDetail">
<link:definition> 100630 - Disclosure - Summary of Other Non-current Assets (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummarizesComponentsOfPropertyAndEquipmentNetDetail" id="Role_DisclosureSummarizesComponentsOfPropertyAndEquipmentNetDetail">
<link:definition> 100640 - Disclosure - Summarizes Components of Property and Equipment, Net (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
<link:definition> 100650 - Disclosure - Property and Equipment, Net - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetail" id="Role_DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetail">
<link:definition> 100660 - Disclosure - Intangible Assets - Summary of Components of Intangible Assets (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" id="Role_DisclosureIntangibleAssetsAdditionalInformationDetail">
<link:definition> 100670 - Disclosure - Intangible Assets - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfEstimatedFutureAmortizationForIntangibleAssetsDetail" id="Role_DisclosureIntangibleAssetsSummaryOfEstimatedFutureAmortizationForIntangibleAssetsDetail">
<link:definition> 100680 - Disclosure - Intangible Assets - Summary of Estimated Future Amortization for Intangible Assets (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfAccruedExpensesDetail" id="Role_DisclosureSummaryOfAccruedExpensesDetail">
<link:definition> 100690 - Disclosure - Summary of Accrued Expenses (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureIndebtednessAdditionalInformationDetail" id="Role_DisclosureIndebtednessAdditionalInformationDetail">
<link:definition> 100700 - Disclosure - Indebtedness - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureIndebtednessSummaryOfDebtFacilitiesDetail" id="Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail">
<link:definition> 100710 - Disclosure - Indebtedness - Summary of Debt Facilities (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail" id="Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail">
<link:definition> 100720 - Disclosure - Indebtedness - Summarizes Total Gross Payments Due under Company's Debt Arrangements (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureEquityAdditionalInformationDetail" id="Role_DisclosureEquityAdditionalInformationDetail">
<link:definition> 100730 - Disclosure - Equity - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
<link:definition> 100740 - Disclosure - Stock Based Compensation - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureAssumptionsForMeasuringFairValuesOfStocksDetail" id="Role_DisclosureAssumptionsForMeasuringFairValuesOfStocksDetail">
<link:definition> 100750 - Disclosure - Assumptions for Measuring Fair Values of Stocks (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureAssumptionsForMeasuringFairValuesOfStocksParentheticalDetail" id="Role_DisclosureAssumptionsForMeasuringFairValuesOfStocksParentheticalDetail">
<link:definition> 100760 - Disclosure - Assumptions for Measuring Fair Values of Stocks (Parenthetical) (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfStockOptionActivityDetail" id="Role_DisclosureSummaryOfStockOptionActivityDetail">
<link:definition> 100770 - Disclosure - Summary of Stock Option Activity (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfStockOptionActivityParentheticalDetail" id="Role_DisclosureSummaryOfStockOptionActivityParentheticalDetail">
<link:definition> 100780 - Disclosure - Summary of Stock Option Activity (Parenthetical) (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfCompanySStockOptionsVestedAndExercisedDetail" id="Role_DisclosureSummaryOfCompanySStockOptionsVestedAndExercisedDetail">
<link:definition> 100790 - Disclosure - Summary of Company's Stock Options Vested and Exercised (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfRestrictedStockAwardActivityDetail" id="Role_DisclosureSummaryOfRestrictedStockAwardActivityDetail">
<link:definition> 100800 - Disclosure - Summary of Restricted Stock Award Activity (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitActivityDetail" id="Role_DisclosureSummaryOfRestrictedStockUnitActivityDetail">
<link:definition> 100810 - Disclosure - Summary of Restricted Stock Unit Activity (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfStockAppreciationRightsActivityDetail" id="Role_DisclosureSummaryOfStockAppreciationRightsActivityDetail">
<link:definition> 100820 - Disclosure - Summary of Stock Appreciation Rights Activity (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfEmployeeStockPurchasePlanActivityAndExpenseDetail" id="Role_DisclosureSummaryOfEmployeeStockPurchasePlanActivityAndExpenseDetail">
<link:definition> 100830 - Disclosure - Summary of Employee Stock Purchase Plan Activity and Expense (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationExpenseByFunctionIncludedWithinConsolidatedStatementsOfOperationsAndComprehensiveLossDetail" id="Role_DisclosureSummaryOfStockBasedCompensationExpenseByFunctionIncludedWithinConsolidatedStatementsOfOperationsAndComprehensiveLossDetail">
<link:definition> 100840 - Disclosure - Summary of Stock-Based Compensation Expense by Function Included within Consolidated Statements of Operations and Comprehensive Loss (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationExpenseByGrantTypeIncludedWithinConsolidatedStatementsOfOperationsAndComprehensiveLossDetail" id="Role_DisclosureSummaryOfStockBasedCompensationExpenseByGrantTypeIncludedWithinConsolidatedStatementsOfOperationsAndComprehensiveLossDetail">
<link:definition> 100850 - Disclosure - Summary of Stock-Based Compensation Expense by Grant Type Included within Consolidated Statements of Operations and Comprehensive Loss (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/Disclosure401KPLANAdditionalInformationDetail" id="Role_Disclosure401KPLANAdditionalInformationDetail">
<link:definition> 100860 - Disclosure - 401 (K) PLAN - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfOtherLossIncomeDetail" id="Role_DisclosureSummaryOfOtherLossIncomeDetail">
<link:definition> 100870 - Disclosure - Summary of Other (Loss) Income (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfLossBeforeProvisionForIncomeTaxesByJurisdictionDetail" id="Role_DisclosureSummaryOfLossBeforeProvisionForIncomeTaxesByJurisdictionDetail">
<link:definition> 100880 - Disclosure - Summary of Loss before Provision for Income Taxes by Jurisdiction (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfProvisionForIncomeTaxesDetail" id="Role_DisclosureSummaryOfProvisionForIncomeTaxesDetail">
<link:definition> 100890 - Disclosure - Summary of Provision for Income Taxes (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureReconciliationBetweenEffectiveTaxRateAndFederalIncomeTaxRateDetail" id="Role_DisclosureReconciliationBetweenEffectiveTaxRateAndFederalIncomeTaxRateDetail">
<link:definition> 100900 - Disclosure - Reconciliation Between Effective Tax Rate and Federal Income Tax Rate (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
<link:definition> 100910 - Disclosure - Income Taxes - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureAnalysisOfDeferredTaxAssetsAndLiabilitiesDetail" id="Role_DisclosureAnalysisOfDeferredTaxAssetsAndLiabilitiesDetail">
<link:definition> 100920 - Disclosure - Analysis of Deferred Tax Assets and Liabilities (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureReconciliationOfBeginningAndEndingAmountOfUnrecognizedTaxBenefitsDetail" id="Role_DisclosureReconciliationOfBeginningAndEndingAmountOfUnrecognizedTaxBenefitsDetail">
<link:definition> 100930 - Disclosure - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
<link:definition> 100940 - Disclosure - Leases - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfLeaseCostsRecognizedUnderTopic842AndOtherInformationPertainingToOperatingLeasesDetail" id="Role_DisclosureSummaryOfLeaseCostsRecognizedUnderTopic842AndOtherInformationPertainingToOperatingLeasesDetail">
<link:definition> 100950 - Disclosure - Summary of Lease Costs Recognized Under Topic 842 and Other Information Pertaining to Operating Leases (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfMaturitiesOfLeaseLiabilitiesAndReconciliationOfLeaseLiabilitiesRecognizedUnderTopic842Detail" id="Role_DisclosureSummaryOfMaturitiesOfLeaseLiabilitiesAndReconciliationOfLeaseLiabilitiesRecognizedUnderTopic842Detail">
<link:definition> 100960 - Disclosure - Summary of Maturities of Lease Liabilities and Reconciliation of Lease Liabilities Recognized Under Topic 842 (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfMaturitiesOfLeaseLiabilitiesAndReconciliationOfLeaseLiabilitiesRecognizedUnderTopic842Detail2" id="Role_DisclosureSummaryOfMaturitiesOfLeaseLiabilitiesAndReconciliationOfLeaseLiabilitiesRecognizedUnderTopic842Detail2">
<link:definition> 100970 - Disclosure - Summary of Maturities of Lease Liabilities and Reconciliation of Lease Liabilities Recognized Under Topic 842 (Detail)2 </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfAggregateFutureMinimumNonCancellableCommitmentsUnderLeasesDetail" id="Role_DisclosureSummaryOfAggregateFutureMinimumNonCancellableCommitmentsUnderLeasesDetail">
<link:definition> 100980 - Disclosure - Summary of Aggregate Future Minimum Non-Cancellable Commitments under Leases (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareDetail" id="Role_DisclosureBasicAndDilutedNetLossPerShareDetail">
<link:definition> 100990 - Disclosure - Basic and Diluted Net Loss Per Share (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareParentheticalDetail" id="Role_DisclosureBasicAndDilutedNetLossPerShareParentheticalDetail">
<link:definition> 101000 - Disclosure - Basic and Diluted Net Loss Per Share (Parenthetical) (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition> 101010 - Disclosure - Commitments and Contingencies - Additional Information (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSummaryOfNonCancelableContractualObligationsArisingFromLongTermContractualArrangementsDetail" id="Role_DisclosureSummaryOfNonCancelableContractualObligationsArisingFromLongTermContractualArrangementsDetail">
<link:definition> 101020 - Disclosure - Summary of Non-Cancelable Contractual Obligations Arising From Long-term Contractual Arrangements (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="Role_DisclosureSubsequentEventAdditionalInformationDetails">
<link:definition> 101030 - Disclosure - Subsequent Event - Additional Information (Details) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureFinancialInformationByQuarterDetail" id="Role_DisclosureFinancialInformationByQuarterDetail">
<link:definition> 101040 - Disclosure - Financial Information by Quarter (Detail) </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.sareptatherapeutics.com/20191231/taxonomy/role/DisclosureFinancialInformationByQuarterDetail2" id="Role_DisclosureFinancialInformationByQuarterDetail2">
<link:definition> 101050 - Disclosure - Financial Information by Quarter (Detail)2 </link:definition>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element id="srpt_AmortizationOfDiscountsPremiumsInvestmentsCashEquivalentAndShortTermInvestment" name="AmortizationOfDiscountsPremiumsInvestmentsCashEquivalentAndShortTermInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_CostOfGoodsSoldExcludingAmortization" name="CostOfGoodsSoldExcludingAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_SettlementAndLicenseCharges" name="SettlementAndLicenseCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_InterestExpenseIncomeAndOtherNet" name="InterestExpenseIncomeAndOtherNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_IssuanceOfCommonStockForCashNetOfOfferingCostsShares" name="IssuanceOfCommonStockForCashNetOfOfferingCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_IssuanceOfCommonStockForCashNetOfOfferingCosts" name="IssuanceOfCommonStockForCashNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallShareOptions" name="AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallShareOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_StockIssuedDuringPeriodSharesStockOptionsAndAppreciationsRightsExercised" name="StockIssuedDuringPeriodSharesStockOptionsAndAppreciationsRightsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_StockIssuedDuringPeriodValueStockOptionsAndStockAppreciationRightsExercised" name="StockIssuedDuringPeriodValueStockOptionsAndStockAppreciationRightsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_StockIssuedDuringPeriodShareForCollaborationAgreement" name="StockIssuedDuringPeriodShareForCollaborationAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_StockIssuedDuringPeriodValueForCollaborationAgreement" name="StockIssuedDuringPeriodValueForCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_NonCashUpFrontPayment" name="NonCashUpFrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_AccretionAmortizationOfDiscountsAndPremiumsShortTermInvestments" name="AccretionAmortizationOfDiscountsAndPremiumsShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_NoncashInterestExpense" name="NoncashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesLeaseLiabilitiesAndOtherLiabilities" name="IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesLeaseLiabilitiesAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_TaxesPaidRelatedToNetShareSettlementOfEquityAwards" name="TaxesPaidRelatedToNetShareSettlementOfEquityAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_RepaymentOfTermLoan" name="RepaymentOfTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_PurchaseOfCappedCallOptions" name="PurchaseOfCappedCallOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_SharesWithheldForTaxIncludedInAccruedExpenses" name="SharesWithheldForTaxIncludedInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_AccruedDebtDiscountAndIssuanceCosts" name="AccruedDebtDiscountAndIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_NonCashOrPartNonCashReclassificationOfLongTermInvestmentsToShortTermInvestments" name="NonCashOrPartNonCashReclassificationOfLongTermInvestmentsToShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_DecemberTwoThousandNineteenTermLoanMember" name="DecemberTwoThousandNineteenTermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_JulyTwoThousandAndSeventeenTermLoanMember" name="JulyTwoThousandAndSeventeenTermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_GainLossFromSaleOfIntangibleAssetsDisclosureTextBlock" name="GainLossFromSaleOfIntangibleAssetsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_AccountsReceivableAndReservesForProductSalesTextBlock" name="AccountsReceivableAndReservesForProductSalesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_EstimatedUsefulLivesAssetsTableTextBlock" name="EstimatedUsefulLivesAssetsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_SummaryOfChangeInReservesForDiscountsAndAllowancesTableTextBlock" name="SummaryOfChangeInReservesForDiscountsAndAllowancesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_SummaryOfReservesForDiscountsAndAllowancesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfReservesForDiscountsAndAllowancesIncludedInConsolidatedBalanceSheetsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_CustomerOneMember" name="CustomerOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_CustomerTwoMember" name="CustomerTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_CustomerThreeMember" name="CustomerThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_AccountsReceivablePaymentTerm" name="AccountsReceivablePaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_LabEquipmentMember" name="LabEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_SoftwareAndComputerEquipmentMember" name="SoftwareAndComputerEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_CommonStockClosingPricePercentage" name="CommonStockClosingPricePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_ProceedsFromLicenseAndCollaborativeAgreement" name="ProceedsFromLicenseAndCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_UpfrontCashPaymentReceived" name="UpfrontCashPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_StockIssuedDuringPeriodValueCollaborationAndLicenseAgreement" name="StockIssuedDuringPeriodValueCollaborationAndLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_RegulatoryAndSalesMilestonesPaymentReceived" name="RegulatoryAndSalesMilestonesPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_RocheMember" name="RocheMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_GenethonMember" name="GenethonMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_GenethonProductsMember" name="GenethonProductsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_OtherLicensedProductsMember" name="OtherLicensedProductsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_StrideBioIncMember" name="StrideBioIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_WarrantAgreementMember" name="WarrantAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_MyonexusTherapeuticsIncMember" name="MyonexusTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_EquityInvestmentAgreementMember" name="EquityInvestmentAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_LysogeneSAMember" name="LysogeneSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_LicenseDevelopmentAndOptionAgreementMember" name="LicenseDevelopmentAndOptionAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_PompeLicenseAgreementMember" name="PompeLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_LacertaTherapeuticsIncMember" name="LacertaTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_SeriesAPreferredStockPurchaseAgreementMember" name="SeriesAPreferredStockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_LicenseAndPurchaseAgreementMember" name="LicenseAndPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_NationwideLicenseAgreementMember" name="NationwideLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_NationwideChildrensHospitalMember" name="NationwideChildrensHospitalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_BioMarinPharmaceuticalIncorporationMember" name="BioMarinPharmaceuticalIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_OtherCountriesMember" name="OtherCountriesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_UniversityOfWesternAustraliaMember" name="UniversityOfWesternAustraliaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_EXONDYSFiftyOneAndFiveAdditionalProductsMember" name="EXONDYSFiftyOneAndFiveAdditionalProductsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_VYONDYSFiftyThreeMember" name="VYONDYSFiftyThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_PaymentForOptionExercise" name="PaymentForOptionExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_PercentageInDevelopmentCosts" name="PercentageInDevelopmentCosts" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_DevelopmentRegulatoryAndSalesMilestonesPayment" name="DevelopmentRegulatoryAndSalesMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_UpfrontCashPaymentUnderAgreements" name="UpfrontCashPaymentUnderAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_DevelopmentRegulatoryAndSalesMilestonesPaymentPerSareptaDevelopmentTargets" name="DevelopmentRegulatoryAndSalesMilestonesPaymentPerSareptaDevelopmentTargets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_DevelopmentRegulatoryAndSalesMilestonesPaymentPerJointDevelopmentTargets" name="DevelopmentRegulatoryAndSalesMilestonesPaymentPerJointDevelopmentTargets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_UpfrontExpense" name="UpfrontExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CashConsiderationUnderAgreementExcludingContingentPayments" name="CashConsiderationUnderAgreementExcludingContingentPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_MilestonePaymentClassifiedAsAccuredExpense" name="MilestonePaymentClassifiedAsAccuredExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_NumberOfDevelopmentMilestone" name="NumberOfDevelopmentMilestone" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_FinalExercisePriceUnderAgreement" name="FinalExercisePriceUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_AdditionalDevelopmentMilestonePaymentsToBePaid" name="AdditionalDevelopmentMilestonePaymentsToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_BusinessAcquisitionTotalConsideration" name="BusinessAcquisitionTotalConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CommonStockPurchased" name="CommonStockPurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_PercentageOfCommonStockOutstanding" name="PercentageOfCommonStockOutstanding" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_DevelopmentRegulatoryAndSalesMilestonePaymentsToBePaid" name="DevelopmentRegulatoryAndSalesMilestonePaymentsToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_UpfrontLicenseFee" name="UpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_DevelopmentMilestonePayment" name="DevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_NumberOfSharesPurchasedUnderAgreement" name="NumberOfSharesPurchasedUnderAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_InvestmentChangeInCarryingValue" name="InvestmentChangeInCarryingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_UpfrontFeeToBePaidOnExecutionOfAgreements" name="UpfrontFeeToBePaidOnExecutionOfAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_PaymentRelatedToRegulatoryAndSalesMilestonePayments" name="PaymentRelatedToRegulatoryAndSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_RoyaltyPaymentExpiryPeriod" name="RoyaltyPaymentExpiryPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_PercentageOfRoyaltyPayments" name="PercentageOfRoyaltyPayments" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_RegulatoryMilestonePayable" name="RegulatoryMilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_UpfrontFeeToBePaidOnCertainAchievement" name="UpfrontFeeToBePaidOnCertainAchievement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_DevelopmentMilestoneAndSettlementUpfrontFeeRecognizedAsResearchAndDevelopmentExpense" name="DevelopmentMilestoneAndSettlementUpfrontFeeRecognizedAsResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_ObligationsDueToDevelopmentRegulatoryCommercialMilestoneAndUpFrontRoyaltyPayments" name="ObligationsDueToDevelopmentRegulatoryCommercialMilestoneAndUpFrontRoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_GainFromSaleOfIntangibleAssetLineItems" name="GainFromSaleOfIntangibleAssetLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_GainFromSaleOfIntangibleAssetTable" name="GainFromSaleOfIntangibleAssetTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_GileadSciencesIncorporationMember" name="GileadSciencesIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_StrategicEquityInvestmentsMember" name="StrategicEquityInvestmentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_WeightedAverageMaturityPeriodOfAvailableForSaleSecurities" name="WeightedAverageMaturityPeriodOfAvailableForSaleSecurities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" name="AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" name="AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" name="AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" name="AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" name="AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" name="AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CashCashEquivalentsAndInvestmentsAmortizedCostBasis" name="CashCashEquivalentsAndInvestmentsAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CashCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_CashCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CashCashEquivalentsAndInvestments" name="CashCashEquivalentsAndInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CashAndCashEquivalentsAmortizedCostBasis" name="CashAndCashEquivalentsAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" name="CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" name="CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CashDepositsAndMoneyMarketFundsMember" name="CashDepositsAndMoneyMarketFundsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_LongTermInvestmentsMember" name="LongTermInvestmentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ProvisionForReservesForDiscountsAndAllowances" name="ProvisionForReservesForDiscountsAndAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_PaymentsCreditsReservesForDiscountsAndAllowances" name="PaymentsCreditsReservesForDiscountsAndAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_ChargebacksMember" name="ChargebacksMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_RebatesMember" name="RebatesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_PromptPayMember" name="PromptPayMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_OtherAccrualsMember" name="OtherAccrualsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ReservesForReductionToAccountsReceivable" name="ReservesForReductionToAccountsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_ReservesForComponentOfAccruedExpenses" name="ReservesForComponentOfAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_ManufacturingRelatedDepositsAndPrepaidExpenseCurrent" name="ManufacturingRelatedDepositsAndPrepaidExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_PrepaidClinicalAndPreclinicalExpensesCurrent" name="PrepaidClinicalAndPreclinicalExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_PrepaidMaintenanceServicesCurrent" name="PrepaidMaintenanceServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_LeaseholdImprovementReceivableCurrent" name="LeaseholdImprovementReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_PrepaidResearchExpensesCurrent" name="PrepaidResearchExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_ManufacturingRelatedDepositsAndPrepaidExpenseNonCurrent" name="ManufacturingRelatedDepositsAndPrepaidExpenseNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_StrategicInvestmentsNoncurrent" name="StrategicInvestmentsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_InLincensedRights" name="InLincensedRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_EXONDYSFiftyOneMember" name="EXONDYSFiftyOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_BioMarinMember" name="BioMarinMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ExpensesIncurredOnCapitalizedPatentsToBeAbandoned" name="ExpensesIncurredOnCapitalizedPatentsToBeAbandoned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_FiniteLivedIntangibleAssetsAmortizationExpenseOneThroughFiveYears" name="FiniteLivedIntangibleAssetsAmortizationExpenseOneThroughFiveYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_AccruedProductRevenueRelatedReserveCurrent" name="AccruedProductRevenueRelatedReserveCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_AccruedContractManufacturingExpenseCurrent" name="AccruedContractManufacturingExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_AccruedMilestoneExpenseCurrent" name="AccruedMilestoneExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_AccruedClinicalAndPreclinicalCostsCurrent" name="AccruedClinicalAndPreclinicalCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_AccruedCollaborationCostSharing" name="AccruedCollaborationCostSharing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_TwoThousandAndTwentyFourSeniorConvertibleNotesMember" name="TwoThousandAndTwentyFourSeniorConvertibleNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_FundamentalChangeMember" name="FundamentalChangeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_BiopharmaCreditPLCAndBiopharmaCreditInvestmentsVMasterLPMember" name="BiopharmaCreditPLCAndBiopharmaCreditInvestmentsVMasterLPMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_TranchAMember" name="TranchAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_TranchBMember" name="TranchBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_MidCapFinancialAmendedAndRestatedCreditAndSecurityAgreementMember" name="MidCapFinancialAmendedAndRestatedCreditAndSecurityAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ConvertibleDebtAndTermLoanAndRevolverAndMortgageLoansMember" name="ConvertibleDebtAndTermLoanAndRevolverAndMortgageLoansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ConvertibleDebtIssuanceCosts" name="ConvertibleDebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_VotingRightsPercentage" name="VotingRightsPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_DebtInstrumentRepurchasePricePercentage" name="DebtInstrumentRepurchasePricePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_NumberOfTranches" name="NumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_LineOfCreditFacilityPrepaymentFeePercentage" name="LineOfCreditFacilityPrepaymentFeePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_TwoThousandAndNineteenTermLoanMember" name="TwoThousandAndNineteenTermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ProceedsFromIssuanceOfCommonStockIncludingPrintingFee" name="ProceedsFromIssuanceOfCommonStockIncludingPrintingFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_UnderwrittenOfferingMember" name="UnderwrittenOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_TwoThousandElevenEquityIncentivePlanMember" name="TwoThousandElevenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_TwoThousandAndThirteenEmployeeStockPurchasePlanMember" name="TwoThousandAndThirteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_TwoThousandFourteenEmploymentCommencementIncentivePlanMember" name="TwoThousandFourteenEmploymentCommencementIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_FormerChiefExecutiveOfficerMember" name="FormerChiefExecutiveOfficerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_OptionsWithServiceConditionsMember" name="OptionsWithServiceConditionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_AwardsWithServiceAndMarketConditionsMember" name="AwardsWithServiceAndMarketConditionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_AwardsWithPerformanceConditionsMember" name="AwardsWithPerformanceConditionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_StockAwardsOrStockUnitsWithServiceConditionsMember" name="StockAwardsOrStockUnitsWithServiceConditionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_CliffVestingPeriod" name="CliffVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_AggregateGrantDateFairValueOfStockOptionsVested" name="AggregateGrantDateFairValueOfStockOptionsVested" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisedPrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisedPrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_RestrictedStockAndRestrictedStockUnitsRSUsMember" name="RestrictedStockAndRestrictedStockUnitsRSUsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" name="DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentAndOtherTaxCredit" name="EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentAndOtherTaxCredit" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_EffectiveIncomeTaxRateReconciliationReturnToProvision" name="EffectiveIncomeTaxRateReconciliationReturnToProvision" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_EffectiveIncomeTaxRateReconciliationImpactOfTaxReformNetOfValuationAllowance" name="EffectiveIncomeTaxRateReconciliationImpactOfTaxReformNetOfValuationAllowance" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_EffectiveIncomeTaxRateReconciliationBasisDifferenceInSubsidiary" name="EffectiveIncomeTaxRateReconciliationBasisDifferenceInSubsidiary" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_AccumulatedCostsRelatedToAcquisition" name="AccumulatedCostsRelatedToAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_UpfrontFeeMilestonePayment" name="UpfrontFeeMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CostRelatedToExerciseOfOption" name="CostRelatedToExerciseOfOption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_SareptaInternationalHoldingsGmbHMember" name="SareptaInternationalHoldingsGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_DeferredTaxAssetsDepreciationAndAmortization" name="DeferredTaxAssetsDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_DeferredTaxAssetsDeferredRevenue" name="DeferredTaxAssetsDeferredRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_DeferredTaxLiabilitiesDebtDiscount" name="DeferredTaxLiabilitiesDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_OperatingLeaseOtherInformationAbstract" name="OperatingLeaseOtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_IncludedInCondensedConsolidatedBalanceSheetAbstract" name="IncludedInCondensedConsolidatedBalanceSheetAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_NumberOfNonRefundableProcessEquipmentFeePayments" name="NumberOfNonRefundableProcessEquipmentFeePayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_QuarterlyCapacityAccessFeePayments" name="QuarterlyCapacityAccessFeePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_AdvanceUpfrontFeeToBePaidOnExecutionOfAgreements" name="AdvanceUpfrontFeeToBePaidOnExecutionOfAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_RequiredNonRefundablePaymentsAtEachTimeOfProcurementOfEquipment" name="RequiredNonRefundablePaymentsAtEachTimeOfProcurementOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ManufacturingAgreementMember" name="ManufacturingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_BrammerBioMALimitedLiabilityCompanyMember" name="BrammerBioMALimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_SupplyAgreementMember" name="SupplyAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ManufacturingCollaborationAgreementMember" name="ManufacturingCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ParagonBioservicesIncMember" name="ParagonBioservicesIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ManufacturingSupplyAgreementMember" name="ManufacturingSupplyAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ClinicalAndCommercialSupplyAgreementMember" name="ClinicalAndCommercialSupplyAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_AldevronLLCMember" name="AldevronLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_ContractResearchOrganizationsMember" name="ContractResearchOrganizationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
<xsd:element id="srpt_AgreementTerm" name="AgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_AutomaticRenewalTerm" name="AutomaticRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_MinimumNumberOfMonthsPriorToExpirationOfTermForRenewal" name="MinimumNumberOfMonthsPriorToExpirationOfTermForRenewal" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_MaximumRequiredAdditionalQuartersForRemittanceOfCapacityAccessFeesBeforeTerminateAgreement" name="MaximumRequiredAdditionalQuartersForRemittanceOfCapacityAccessFeesBeforeTerminateAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_CashPaymentUnderAgreements" name="CashPaymentUnderAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_NumberOfDedicatedCleanRoomSuite" name="NumberOfDedicatedCleanRoomSuite" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_NumberOfAdditionalCleanRoomSuitesAvailableOnOptionalReserve" name="NumberOfAdditionalCleanRoomSuitesAvailableOnOptionalReserve" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_AgreementExpirationDate" name="AgreementExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_UsageFeesPerAnnumPerCleanRoomSuite" name="UsageFeesPerAnnumPerCleanRoomSuite" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CleanRoomSuiteReservationFees" name="CleanRoomSuiteReservationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_PercentageOfCreditOnCleanRoomUseFeeIfThresholdMet" name="PercentageOfCreditOnCleanRoomUseFeeIfThresholdMet" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_CleanRoomSuiteReservationFeesPayments" name="CleanRoomSuiteReservationFeesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_AgreementExtensionTerm" name="AgreementExtensionTerm" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
<xsd:element id="srpt_PercentageOfPrepaymentsCreditedBackEqualToBatchInvoiceAmount" name="PercentageOfPrepaymentsCreditedBackEqualToBatchInvoiceAmount" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
<xsd:element id="srpt_Prepayments" name="Prepayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_CancellableFutureCommitments" name="CancellableFutureCommitments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
<xsd:element id="srpt_FinalSalePriceUnderAgreement" name="FinalSalePriceUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
<xsd:element id="srpt_FDAMember" name="FDAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>

9 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  Sarepta Therapeutics, Inc.        S-8 POS     3/28/24    4:220K                                   Donnelley … Solutions/FA
 3/28/24  Sarepta Therapeutics, Inc.        S-8 POS     3/28/24    4:220K                                   Donnelley … Solutions/FA
 3/28/24  Sarepta Therapeutics, Inc.        S-8 POS     3/28/24    4:220K                                   Donnelley … Solutions/FA
 3/28/24  Sarepta Therapeutics, Inc.        S-8 POS     3/28/24    4:220K                                   Donnelley … Solutions/FA
 2/28/24  Sarepta Therapeutics, Inc.        10-K       12/31/23  119:18M                                    Donnelley … Solutions/FA
 2/28/23  Sarepta Therapeutics, Inc.        10-K       12/31/22  119:23M                                    Donnelley … Solutions/FA
 3/02/22  Sarepta Therapeutics, Inc.        S-3ASR      3/02/22    4:438K                                   Donnelley … Solutions/FA
 3/01/22  Sarepta Therapeutics, Inc.        10-K       12/31/21  121:20M                                    Donnelley … Solutions/FA
 3/01/21  Sarepta Therapeutics, Inc.        10-K       12/31/20  124:22M                                    ActiveDisclosure/FA
↑Top
Filing Submission 0001564590-20-006769   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., May 11, 10:55:18.2pm ET